Although some characteristics of TB therapy, such as interruption of treatment, are well known predictors of multi-drug resistance, other aspects of treatment that reflect the health-care system, such as the drugs used and the length of therapy, must be studied to help improve control programmes. For example, one of the studies that we reviewed found that no standard therapy in the initial or secondary phase of treatment was associated with an unsuccessful outcome or death.